Glutamic acid

Overview

A peptide that is a homopolymer of glutamic acid.

Indication

Considered to be nature's "Brain food" by improving mental capacities; helps speed the healing of ulcers; gives a "lift" from fatigue; helps control alcoholism, schizophrenia and the craving for sugar.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules	2019/01/31	NCT03824535	Phase 2	Completed	Andrei Iagaru
Glutamine PET Imaging Colorectal Cancer	2017/09/08	NCT03275974	Phase 1	Active, not recruiting	M.D. Anderson Cancer Center
18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules	2015/05/19	NCT02448225	Phase 2	Completed	Vanderbilt-Ingram Cancer Center
The Influence of Glutamate on Memory in Humans	2009/09/21	NCT00980408	Not Applicable	Completed	University Hospital, Bonn
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer	2006/08/29	NCT00369564	Phase 3	Completed	University of South Florida
A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients	2001/08/31	NCT00000768	Phase 1	Completed	National Institute of Allergy and Infectious Diseases (NIAID)

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Aminosyn II	ICU Medical Inc.	0990-7171	INTRAVENOUS	1107 mg in 100 mL	5/4/2022
Plenamine	B. Braun Medical Inc.	0264-4500	INTRAVENOUS	749 mg in 100 mL	4/21/2023
Premasol - sulfite-free (Amino Acid)	Baxter Healthcare Corporation	0338-1131	INTRAVENOUS	0.30 g in 100 mL	8/4/2022
TrophAmine	B. Braun Medical Inc.	0264-1933	INTRAVENOUS	0.5 g in 100 mL	8/22/2022
Kabiven	Fresenius Kabi USA, LLC	63323-712	INTRAVENOUS	164 mg in 100 mL	8/2/2023
Aminosyn II	ICU Medical Inc.	0990-7172	INTRAVENOUS	738 mg in 100 mL	5/4/2022
Perikabiven	Fresenius Kabi USA, LLC	63323-714	INTRAVENOUS	116 mg in 100 mL	8/7/2023
Aminosyn-PF	ICU Medical Inc.	0990-4178	INTRAVENOUS	576 mg in 100 mL	9/21/2021
Premasol - sulfite-free (Amino Acid)	Baxter Healthcare Corporation	0338-1130	INTRAVENOUS	0.50 g in 100 mL	8/4/2022
ProSol	Baxter Healthcare Corporation	0338-0499	INTRAVENOUS	1.02 g in 100 mL	10/7/2020

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
OLIMEL N9E Emulsion for Infusion	Ajinomoto Health & Nutrition North America Inc. (Intermediate), Baxter S.A	SIN16890P	EMULSION	2.84g/L	10/20/2023
KABIVEN PERIPHERAL EMULSION FOR INFUSION	FRESENIUS KABI AB, FRESENIUS KABI AUSTRIA GMBH	SIN11718P	INJECTION	1.2 g/l	11/16/2001
PERIOLIMEL N4E Emulsion for Infusion	Ajinomoto Health & Nutrition North America Inc. (Intermediate), Baxter S.A	SIN16888P	EMULSION	1.26g/L	10/20/2023
AMINOPLASMAL B.BRAUN 10% E SOLUTION FOR INFUSION	B. Braun Melsungen AG	SIN15411P	INFUSION, SOLUTION	7.20g/1000ml	1/23/2018
NUTRIFLEX® OMEGA SPECIAL B. BRAUN EMULSION FOR INFUSION	B. Braun Melsungen AG	SIN16734P	INJECTION, EMULSION	4.908g/1000ml	3/7/2023
VAMINOLACT INTRAVENOUS SOLUTION	FRESENIUS KABI AUSTRIA GMBH	SIN07428P	INJECTION	7.1 g/1000 ml	5/12/1993
OLIMEL N7E Emulsion for Infusion	Ajinomoto Health & Nutrition North America Inc. (Intermediate), Baxter S.A	SIN16889P	EMULSION	2.21g/L	10/20/2023
AMINOPLASMAL-15% INFUSION	B BRAUN MELSUNGEN AG	SIN08352P	INJECTION	16.2 g/l	9/14/1995
KABIVEN EMULSION FOR INFUSION	FRESENIUS KABI AB, FRESENIUS KABI AUSTRIA GMBH	SIN11657P	INJECTION	1.6 g/1000 ml	9/4/2001
PRIMENE 10% AMINO ACID INTRAVENOUS INFUSION	BIEFFE MEDITAL S.P.A.	SIN10252P	INJECTION	10 g/l	9/23/1998

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
VAMINOLACT I.V. SOLUTION	N/A	FRESENIUS KABI HONG KONG LIMITED	N/A	N/A	10/14/1992
OLIMEL N9E EMULSION FOR INFUSION	N/A	Baxter Healthcare Ltd	N/A	N/A	10/24/2013
NUTRIFLEX OMEGA SPECIAL EMULSION FOR INFUSION	N/A	B BRAUN MEDICAL SA	N/A	N/A	1/11/2012
PERIOLIMEL N4E EMULSION FOR INFUSION	N/A	Baxter Healthcare Ltd	N/A	N/A	10/24/2013
NUTRIFLEX OMEGA PLUS EMULSION FOR INFUSION	N/A	B BRAUN MEDICAL SA	N/A	N/A	1/11/2012

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
OLIMEL N5-860E Emulsion for intravenous infusion	197417	Baxter Healthcare Pty Ltd	Medicine	A	8/9/2013
Olimel N12-640 emulsion for intravenous infusion bag.	303755	Baxter Healthcare Pty Ltd	Medicine	A	7/1/2019
GLAMIN amino acids/dipeptides 250mL intravenous infusion injection bottle	77749	Fresenius Kabi Australia Pty Ltd	Medicine	A	5/29/2002
Advanced Medicine Hepatic Detox	95172	Advanced Medicine Australia Pty Ltd	Medicine	A	6/24/2003
OLIMEL N7-960E Emulsion for intravenous infusion	197418	Baxter Healthcare Pty Ltd	Medicine	A	8/9/2013
VAMIN 14 ELECTROLYTE FREE 500mL injection bottle	14455	Fresenius Kabi Australia Pty Ltd	Medicine	A	9/5/1991
Orthoplex Hydrozyme	19983	Bio Concepts Pty Ltd	Medicine	A	10/3/1991
OLIMEL N12-640E Emulsion for Intravenous Infusion Bag	303864	Baxter Healthcare Pty Ltd	Medicine	A	7/1/2019
PRIMENE 10% amino acids solution for injection Bottle	79618	Baxter Healthcare Pty Ltd	Medicine	A	4/23/2002
VAMIN 18 ELECTROLYTE FREE 500mL injection bottle	14454	Fresenius Kabi Australia Pty Ltd	Medicine	A	9/5/1991

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
FORMULA 22158	therapeutic foods co.	00191531	Capsule - Oral	7 MG / CAP	5/18/1994
BROMELAIN-PAPAIN	seroyal international inc.	00565504	Tablet - Oral	100 MG	12/31/1981
OLIMEL 5.7% E	baxter corporation	02352532	Emulsion - Intravenous	2.84 G / L	1/19/2011
AMINOSYN-PF 10%	hospira healthcare ulc	00731366	Solution - Intravenous	820 MG / 100 ML	12/31/1990
AMINOSYN II 8.5% WITH 50% DEXTROSE	hospira healthcare ulc	00742767	Solution - Intravenous	314 MG / 100 ML	12/31/1988
PRIMENE 10%-LIQ IV	clintec nutrition company	02161192	Liquid - Intravenous	1 G / 100 ML	12/31/1995
OLIMEL 7.6% E	baxter corporation	02477955	Emulsion - Intravenous	3.79 G / L	10/25/2018
PRIMENE 10%	baxter corporation	02236875	Liquid - Intravenous	1 G / 100 ML	11/14/1997
AMINOSYN II WITH ELECTROLYTES IN DEXTROSE INJECTION WITH CALCIUM	hospira healthcare ulc	00851574	Solution - Intravenous	314 MG / 100 ML	12/30/1996
AMINOSYN II 7% WITH 10% DEXTROSE	hospira healthcare ulc	00742740	Solution - Intravenous	258 MG / 100 ML	12/31/1988

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Bexorg Partners with Biohaven to Advance CNS Drug Development Using AI-Driven Whole-Brain Discovery Platform

3 months ago

Bexorg announced a multi-program research collaboration with Biohaven to identify and advance next-generation therapies for central nervous system disorders using its novel whole-brain discovery platform.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access